BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin’s lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to treat solid tumors targeting FCYRIIB; and BT-001 in phase 1 clinical trial for the treatment of solid tumors targeting Cytotoxic T lymphocyte-associated protein-4. The company has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BI-1206, BI-1808, and BT-001 in combination with Keytruda; and licensing agreement with CASI pharmaceuticals for BI-1206. The company was incorporated in 1996 and is based in Lund, Sweden.
Metrics to compare | BINV | Peers Peers - average of corresponding metrics from companies closely matching BINV: CRNOSb_old, IVACC, EGTX, APTA, ATORX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBINVPeersSector |
---|---|---|---|---|
P/E Ratio | −6.7x | −1.8x | −0.6x | |
PEG Ratio | 0.27 | −0.04 | 0.00 | |
Price/Book | 2.4x | 1.6x | 2.6x | |
Price / LTM Sales | 49.0x | 19.5x | 3.1x | |
Upside (Analyst Target) | 129.3% | 113.9% | 58.1% | |
Fair Value Upside | Unlock | 25.9% | 9.2% | Unlock |